Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Shankar

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Neurology and Therapy|April 15, 2023
Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE StudiesLilyana Amezcua, Yang Mao-Draayer, Wendy S Vargas, et al.
Neurology and Therapy|June 27, 2024
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 StudyBarry A Singer, Sibyl Wray, Mark Gudesblatt, et al.
Annals of the Rheumatic Diseases|August 21, 2012
Pomalidomide is effective for prevention and treatment of experimental skin fibrosisSimon Weingärtner, Pawel Zerr, Michal Tomcik, et al.
Neurology and Therapy|June 16, 2025
Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USASophia Woodson, Edward J Gettings, Chu-Yueh Guo, et al.
Neurology and Therapy|June 16, 2025
Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple SclerosisSophia Woodson, Edward J Gettings, Chu-Yueh Guo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2008
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)E A Eisenhauer, P Therasse, J Bogaerts, et al.
Advances in Therapy|February 25, 2022
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 StudySibyl Wray, Florian Then Bergh, Annette Wundes, et al.
Advances in Therapy|February 18, 2026
Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims AnalysisAhmed Z Obeidat, Michelle Betz, Rebecca Straus Farber, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 31, 2023
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 studyBarry A Singer, Douglas L Arnold, Jelena Drulovic, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Neurology and Therapy|April 15, 2023
Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE StudiesLilyana Amezcua, Yang Mao-Draayer, Wendy S Vargas, et al.
Neurology and Therapy|June 27, 2024
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 StudyBarry A Singer, Sibyl Wray, Mark Gudesblatt, et al.
Annals of the Rheumatic Diseases|August 21, 2012
Pomalidomide is effective for prevention and treatment of experimental skin fibrosisSimon Weingärtner, Pawel Zerr, Michal Tomcik, et al.
Neurology and Therapy|June 16, 2025
Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USASophia Woodson, Edward J Gettings, Chu-Yueh Guo, et al.
Neurology and Therapy|June 16, 2025
Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple SclerosisSophia Woodson, Edward J Gettings, Chu-Yueh Guo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2008
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)E A Eisenhauer, P Therasse, J Bogaerts, et al.
Advances in Therapy|February 25, 2022
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 StudySibyl Wray, Florian Then Bergh, Annette Wundes, et al.
Advances in Therapy|February 18, 2026
Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims AnalysisAhmed Z Obeidat, Michelle Betz, Rebecca Straus Farber, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 31, 2023
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 studyBarry A Singer, Douglas L Arnold, Jelena Drulovic, et al.
Pageof 7